Exchange Traded Concepts LLC Raises Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Exchange Traded Concepts LLC increased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 4.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 75,095 shares of the specialty pharmaceutical company’s stock after buying an additional 3,402 shares during the period. Exchange Traded Concepts LLC’s holdings in Collegium Pharmaceutical were worth $2,151,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in COLL. Victory Capital Management Inc. raised its position in Collegium Pharmaceutical by 43.6% in the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock valued at $27,461,000 after purchasing an additional 215,874 shares during the period. Emerald Advisers LLC grew its stake in Collegium Pharmaceutical by 27.2% in the third quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock worth $31,967,000 after purchasing an additional 177,129 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after purchasing an additional 175,892 shares in the last quarter. Emerald Mutual Fund Advisers Trust grew its stake in Collegium Pharmaceutical by 24.9% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 662,291 shares of the specialty pharmaceutical company’s stock worth $25,591,000 after purchasing an additional 131,835 shares in the last quarter. Finally, Empowered Funds LLC acquired a new position in Collegium Pharmaceutical in the third quarter worth about $4,693,000.

Insider Activity

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the sale, the executive vice president now owns 119,184 shares of the company’s stock, valued at approximately $3,937,839.36. The trade was a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 3.98% of the company’s stock.

Analysts Set New Price Targets

COLL has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Piper Sandler reiterated a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Finally, Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $43.80.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ COLL opened at $32.59 on Monday. The firm’s 50-day moving average price is $30.74 and its two-hundred day moving average price is $34.15. The stock has a market capitalization of $1.05 billion, a P/E ratio of 14.05 and a beta of 0.82. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 52-week low of $28.39 and a 52-week high of $42.29.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.